Clinical Laserthermia Systems AB Class B AI Stock Analysis
Want to see SE:CLS.B full AI Analyst Report?
Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis
Clinical Laserthermia Systems AB Class B
(Nasdaq OMX AB:CLS.B)
The overall score is severely depressed by the company's fundamental weakness. The primary drag is the financial performance, marked by declining revenue, negative margins, and ongoing cash burn that threatens the debt-free balance sheet. This is compounded by a persistent technical downtrend and a negative P/E ratio that underscores the lack of profitability. The company's survival hinges on achieving profitability or securing further capital.
Clinical Laserthermia Systems AB Class B (CLS.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 78.99M
- Dividend Yield
- ―
- Average Volume (3M)
- 71.44K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.38
- Revenue Growth
- -47.42%
- EPS Growth
- 44.01%
- Country
- Sweden
- Employees
- 13
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model
Company Description
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The...
How the Company Makes Money
CLS generates revenue primarily from selling its laser ablation/thermotherapy platform and associated consumables used in clinical procedures. Key revenue streams typically include: (1) system/platform sales (capital equipment) to hospitals and clini...
Clinical Laserthermia Systems AB Class B Financial Statement Overview
Summary
Financial health is critically weak. Revenue declined 12% with negative gross profit, and the company remains deeply unprofitable. Although the balance sheet is debt-free, equity is eroding rapidly due to persistent losses, and cash flow remains negative, indicating a continued cash burn that will likely require additional funding.
Income Statement
22NegativeBalance Sheet
38NegativeCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.56M | 17.49M | 18.78M | 8.27M | 6.27M | 2.25M |
| Gross Profit | -4.10M | -29.00M | 10.42M | 3.00M | -2.79M | -3.63M |
| EBITDA | -37.95M | -26.41M | -44.76M | -68.41M | -57.84M | -57.05M |
| Net Income | -39.49M | -41.61M | -47.62M | -79.79M | -70.66M | -63.62M |
Balance Sheet | ||||||
| Total Assets | 66.57M | 76.49M | 78.56M | 57.73M | 49.51M | 66.74M |
| Cash, Cash Equivalents and Short-Term Investments | 3.87M | 21.55M | 22.51M | 15.33M | 10.59M | 31.17M |
| Total Debt | 0 | 0 | 224.00K | 454.00K | 30.68M | 273.50K |
| Total Liabilities | 22.07M | 10.00M | 12.88M | 14.20M | 41.64M | 45.55M |
| Stockholders Equity | 47.84M | 69.67M | 68.72M | 45.77M | 9.22M | 21.79M |
Cash Flow | ||||||
| Free Cash Flow | -32.35M | -36.00M | -58.92M | -71.95M | -71.25M | -66.73M |
| Operating Cash Flow | -25.04M | -33.20M | -56.45M | -66.45M | -70.69M | -66.17M |
| Investing Cash Flow | -7.31M | -2.80M | -7.47M | -5.50M | -886.00K | -408.00K |
| Financing Cash Flow | 20.02M | 35.04M | 71.10M | 76.69M | 61.84M | 85.88M |
Clinical Laserthermia Systems AB Class B Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Negative. The current price of 1.63 is below the 20-day moving average (MA) of 1.75, below the 50-day MA of 1.79, and below the 200-day MA of 3.45, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 32.79 is Neutral, neither overbought nor oversold. The STOCH value of 22.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLS.B.
Clinical Laserthermia Systems AB Class B Peers Comparison
Overall Rating
SE:CRAD.B64Neutral
SE:RAY.B63Neutral
SE:PAX57Neutral
SE:SPAGO42Neutral
SE:SPEC40Underperform
SE:CLS.B38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 64Neutral | SEK 827.29M | 17.41 | 13.23% | 0.41% | -8.76% | 103.87% | |
| 63Neutral | SEK 5.98B | 28.95 | 22.61% | 2.29% | 3.16% | -5.78% | |
| 57Neutral | SEK 1.55B | -306.14 | -1.22% | ― | 34.05% | -144.96% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | SEK 35.13M | -1.10 | -87.37% | ― | -97.52% | 31.31% | |
| 40Underperform | SEK 19.12M | -0.11 | -57.15% | ― | ― | 78.15% | |
| 38Underperform | SEK 78.99M | -1.21 | -66.41% | ― | -47.42% | 44.01% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:CLS.B | Clinical Laserthermia Systems AB Class B | 1.63 | -5.10 | -75.81% | |
| SE:PAX | Paxman AB | 66.80 | 4.80 | 7.74% | |
| SE:RAY.B | RaySearch Laboratories AB Class B | 174.30 | -36.24 | -17.21% | |
| SE:SPEC | SpectraCure AB | 0.01 | -0.12 | -89.92% | |
| SE:CRAD.B | C-Rad AB Class B | 24.50 | -10.09 | -29.18% | |
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.06 | -56.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 03, 2026
